APA (7th ed.) Citation

M, F., J, W., A, G., F, F., S, R., AM, F., . . . P, C. (2022). Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(19), 4203. https://doi.org/10.1158/1078-0432.CCR-22-0433

Chicago Style (17th ed.) Citation

M, Fürstenau, et al. "Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 19 (2022): 4203. https://doi.org/10.1158/1078-0432.CCR-22-0433.

MLA (9th ed.) Citation

M, Fürstenau, et al. "Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 19, 2022, p. 4203, https://doi.org/10.1158/1078-0432.CCR-22-0433.